U.S. Industrials Stock News

Recently, Jim Cramer highlighted Dover Corporation’s strong quarterly results, pointing to its pivot toward data center, aerospace, and clean energy markets, alongside management’s decision to raise full-year earnings guidance. This shift toward higher-growth, technology-driven end markets reinforces Dover’s effort to reposition its portfolio toward areas that may offer richer margins and more resilient demand. Next, we’ll examine how Dover’s raised earnings outlook and push into data...

Applied Digital (APLD) just locked in a fresh $100 million development loan from Macquarie Group, and the stock reacted quickly, jumping as investors digested what that firepower means for its AI data center buildout. See our latest analysis for Applied Digital. The loan news lands on top of a powerful run, with a roughly 31.7 percent one month share price return and a long term total shareholder return well into four digits, indicating that momentum remains strong despite sharp swings. If...

UnitedHealth Group (UNH) has been grinding through a stretch of mixed returns, with the stock down sharply year to date but edging slightly higher over the past month as investors reassess its longer term earnings power. See our latest analysis for UnitedHealth Group. That backdrop of tougher sentiment has kept a lid on the shares, with a steep year to date share price decline and weak multi year total shareholder returns. Recent regulatory headlines and earnings updates have only nudged the...

Brinker International (EAT) just caught investors attention after a cluster of bullish analyst upgrades, tied to stronger fundamentals, leaner costs, and busier dining rooms, pushed the stock meaningfully higher this month. See our latest analysis for Brinker International. Those upgrades are landing on top of solid momentum, with an 11.92% 1 month share price return and a powerful 3 year total shareholder return of 358.56%. This suggests investors are steadily repricing Brinker's earnings...

Air Products and Chemicals (APD) has been grinding through a weaker stretch, with the stock down about 5% over the past month and roughly 11% in the past 3 months. See our latest analysis for Air Products and Chemicals. That recent slide comes on top of a weak year to date, with the share price down sharply in 2024 and longer term total shareholder returns barely positive over five years. This suggests momentum has clearly faded as investors reassess growth versus risk. If APD’s pullback has...

If you have been wondering whether Mohawk Industries at around $108 a share is a bargain or a value trap, you are not alone. This article is designed to cut through the noise and focus squarely on what the numbers say. The stock is down about 2.6% over the last week, roughly 1.2% over the last month, and about 6.3% year to date, while still sitting on a 10.8% gain over three years despite a 22.7% slide over five years. Recent headlines have centered on the housing and renovation cycle,...

Aristotle Capital Boston’s decision to fully exit Carter's (CRI), citing weakening fundamentals and a cloudy strategic path, put the stock back under the microscope for investors wondering whether the selloff has gone too far. See our latest analysis for Carter's. The latest move came after a tough stretch for investors, with Carter's year to date share price return sitting sharply negative. However, a roughly 6 percent 1 month share price gain hints that selling pressure may be easing, while...

Hut 8 partnership puts Jacobs Solutions in the AI infrastructure spotlight Jacobs Solutions (J) just landed a high profile role as EPCM partner to Hut 8 Corp. on a major AI infrastructure build, a deal that underlines rising demand for Jacobs advanced facilities expertise. See our latest analysis for Jacobs Solutions. The Hut 8 deal lands just as Jacobs navigates a choppy year, with a modest year to date share price return of 2.05 percent, but a stronger 39.44 percent three year total...

The9 (NCTY) has turned in a starkly weaker set of H1 2025 numbers, with revenue falling to about CNY 19.6 million and basic EPS sliding to around CNY minus 14.4, alongside a net loss excluding extra items of roughly CNY 73.7 million. The company has seen revenue drop from about CNY 82.0 million in H2 2023 to roughly CNY 19.6 million in H2 2024, while EPS has swung from approximately CNY 34.6 to CNY minus 14.4 over the same stretch. This underscores how quickly margins have compressed as the...

In recent days, analysts at Wells Fargo and BTIG reaffirmed positive views on Atlassian, while corporate insider sentiment turned negative due to increased selling, including a sale by CTO Rajeev Rajan Bashyam earlier this quarter. Atlassian also lifted its cloud revenue outlook for fiscal 2026 and reiterated a long-term 20% annual growth target, suggesting management still sees strong demand despite concerns about AI-related disruption. We’ll now examine how Atlassian’s higher cloud revenue...

If you are wondering whether Honeywell International is a bargain or a value trap at around $196 a share, you are not alone. This breakdown is designed to cut through the noise for long term investors. Despite being down 13.1% year to date and 6.4% over the last year, the stock has shown some resilience recently, with a 3.1% gain over the past month, even though it slipped 0.8% in the last week. Recent headlines have focused on Honeywell's push deeper into automation and digital industrial...

Wondering if Amazon.com is still attractive at today’s price, or if most of the upside has already been realized? This breakdown will help you assess whether the current market valuation makes sense. Over the last week the stock is up 2.6%, with a 3.5% gain over the past month and a 3.7% return year to date. The longer term 3 year return of 167.9% and 5 year return of 39.1% show how quickly sentiment around Amazon.com can shift. Recent headlines have focused on Amazon.com increasing its...

Avadel Pharmaceuticals has completed patient enrollment in REVITALYZ, its Phase 3 trial testing once-at-bedtime LUMRYZ for idiopathic hypersomnia, advancing the drug beyond its existing US FDA-approved use in narcolepsy. This milestone, paired with LUMRYZ’s Orphan Drug Designation in idiopathic hypersomnia, could meaningfully influence expectations for the drug’s long-term role in sleep medicine. We’ll now explore how completion of REVITALYZ enrollment, and the prospect of label expansion...

If you are wondering whether Realty Income is still a dependable bargain or if the easy money has already been made, this breakdown will help you evaluate whether the current price makes sense for long term investors. The stock is up 13.1% over the past year and 21.8% over five years, but its 7.7% year-to-date gain and flat 30 day move suggest the market is pausing to reassess what it is really worth at around $56.67. Recent headlines have focused on Realty Income's continued portfolio...

Deere (DE) has quietly slipped about 3% over the past month, even as its year to date return still sits in the low teens. That disconnect is exactly where the valuation story starts to get interesting for long term investors. See our latest analysis for Deere. The latest pullback comes after a strong run, with Deere still posting a double digit year to date share price return and a robust five year total shareholder return. This suggests momentum is pausing rather than breaking as investors...

Morgan Stanley recently completed several fixed-income offerings totaling about US$22.76 million in senior unsecured notes maturing between 2030 and 2035, while its investment management arm reported that its ETF platform surpassed US$10.00 billion in assets under management across 18 products. Beyond adding new funding and products, this growth in ETFs underscores how Morgan Stanley is deepening fee-based, recurring revenue streams across its wealth and asset management franchise. We’ll now...

Option Care Health (OPCH) has quietly put together a strong run, with the stock up around 10% over the past month and more than 40% this year, outpacing many healthcare peers. See our latest analysis for Option Care Health. That backdrop fits a broader pattern, with Option Care Health’s roughly 43% year to date share price return and solid multi year total shareholder returns suggesting that momentum is still building as investors reassess its growth and risk profile. If Option Care’s run has...

Telsey Advisory’s upgrade on Victoria's Secret (VSCO) to Outperform, tied to better momentum with younger shoppers and beauty, has come right as the stock is riding a steep multi month rally. See our latest analysis for Victoria's Secret. That call from Telsey lands after a sharp reset in expectations, with Victoria's Secret delivering a roughly 120 percent 3 month share price return and a 34 percent one year total shareholder return, suggesting momentum is firmly rebuilding around the...

Delta Air Lines (DAL) just put a date on a major leadership transition, with long time president Glen Hauenstein set to retire in February 2026 and commercial chief in waiting Joe Esposito stepping up. See our latest analysis for Delta Air Lines. The leadership shuffle lands at a time when investors are already leaning optimistic on Delta, with a roughly 21 percent 1 month share price return and a powerful 3 year total shareholder return above 120 percent. This suggests momentum is still...

PBF Energy has recently grappled with conflicting analyst views, as Wolfe Research downgraded the refiner on sector headwinds while Mizuho upgraded its rating amid ongoing margin and demand uncertainties in US refining. At the same time, the company has highlighted climate and transition themes through its 2025 TCFD report and continued renewable-fuels efforts, underscoring how environmental policy and decarbonization risks are increasingly central to its long-term outlook. We’ll now examine...

Eos Energy Enterprises recently outlined a proposed US$500 million capital raise, fresh analyst coverage including JP Morgan’s Neutral initiation, and ongoing progress scaling its zinc-based battery manufacturing for renewable and AI data center markets, all against a backdrop of evolving clean energy policy support and expiring tax credits. The company’s emphasis on a mostly domestic, critical‑mineral‑light supply chain and a globally replicable manufacturing model stands out as a...

EMCOR Group, Inc. recently approved a 60% increase in its regular quarterly dividend to US$0.40 per share from US$0.25, with the higher payout expected to begin in the first quarter of 2026 alongside an expanded US$500.00 million share repurchase program and higher 2025 earnings guidance. This combination of a larger dividend, additional buyback capacity, and raised profit outlook highlights management’s confidence in EMCOR’s cash generation and long-term earnings power. We’ll now examine...

Rhythm Pharmaceuticals (RYTM) has quietly turned into one of this year’s stronger biotech performers, with the stock up about 87% year to date and roughly doubling over the past year. See our latest analysis for Rhythm Pharmaceuticals. That move has come with real momentum behind it, with a roughly 10% 1 month share price return feeding into an almost 87% year to date gain and a standout 1 year total shareholder return just over 100%. If Rhythm’s run has you rethinking your biotech exposure,...

Liberty Latin America (LILA) has quietly slipped about 5% over the past week and 3% over the past month, even though the stock is still up roughly 25% year to date. See our latest analysis for Liberty Latin America. That recent pullback in the share price, now around $7.98, comes after a strong year to date share price return of about 25%. However, the five year total shareholder return is still negative, suggesting momentum is improving from a low base but not yet fully convincing over the...